Link to paper: Houston Methodist Omicron study
“We next analyzed Omicron vaccine breakthrough cases (Table 1, Table 2). We found 430 of the 862 total Omicron patients (49.9%) for whom we have whole genome sequence data met the CDC definition of vaccine breakthrough cases (Table 1, Table 2). There was no simple relationship between the time elapsed since administration of the second vaccination dose and the date of vaccination breakthrough. These 430 patients received either two doses of the Pfizer-BioNTech BNT162b2 (n = 299, 69%) or Moderna mRNA-1273 (n = 111, 26%), or one dose of J&J/Janssen JNJ-78436735 (n = 20, 5%) vaccine. This distribution reflects the majority use of BNT162b2 vaccination doses in our health system. Compared to either Alpha or Delta patients, a significantly greater percentage of patients with breakthrough cases was caused by the Omicron VOC (49.9% compared to 3.2% and 24.1% for Alpha and Delta VOCs, respectively) (Table 1, Table 2). We next analyzed individuals with breakthrough cases after receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine. We found that 85 (9.9%) of the 862 Omicron patients met this criteria.”
“We next analyzed Omicron vaccine breakthrough cases (Table 1, Table 2). We found 430 of the 862 total Omicron patients (49.9%) for whom we have whole genome sequence data met the CDC definition of vaccine breakthrough cases (Table 1, Table 2). There was no simple relationship between the time elapsed since administration of the second vaccination dose and the date of vaccination breakthrough. These 430 patients received either two doses of the Pfizer-BioNTech BNT162b2 (n = 299, 69%) or Moderna mRNA-1273 (n = 111, 26%), or one dose of J&J/Janssen JNJ-78436735 (n = 20, 5%) vaccine. This distribution reflects the majority use of BNT162b2 vaccination doses in our health system. Compared to either Alpha or Delta patients, a significantly greater percentage of patients with breakthrough cases was caused by the Omicron VOC (49.9% compared to 3.2% and 24.1% for Alpha and Delta VOCs, respectively) (Table 1, Table 2). We next analyzed individuals with breakthrough cases after receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine. We found that 85 (9.9%) of the 862 Omicron patients met this criteria.”
